Arcturus Therapeutics (NASDAQ:ARCT – Get Rating) released its quarterly earnings results on Tuesday. The biotechnology company reported ($0.82) EPS for the quarter, beating analysts' consensus estimates of ($1.90) by $1.08, Fidelity Earnings reports. Arcturus Therapeutics had a negative return on equity of 81.21% and a negative net margin of 1,282.62%. During the same period last year, the firm posted ($2.07) EPS.
Arcturus Therapeutics Stock Down 4.1 %
Shares of ARCT traded down $0.75 on Wednesday, reaching $17.48. The company's stock had a trading volume of 678,823 shares, compared to its average volume of 603,511. Arcturus Therapeutics has a twelve month low of $11.70 and a twelve month high of $58.45. The stock has a market capitalization of $461.80 million, a PE ratio of -2.32 and a beta of 2.71. The company has a current ratio of 3.05, a quick ratio of 3.05 and a debt-to-equity ratio of 0.21. The firm has a fifty day moving average of $17.11 and a 200-day moving average of $20.72.
Get
Arcturus Therapeutics alerts:
Wall Street Analysts Forecast Growth
A number of analysts have weighed in on the stock. The Goldman Sachs Group decreased their target price on shares of Arcturus Therapeutics from $14.00 to $8.00 and set a "sell" rating for the company in a research report on Tuesday, May 24th. Raymond James downgraded Arcturus Therapeutics from a "market perform" rating to an "underperform" rating in a research note on Wednesday. Barclays reduced their price objective on shares of Arcturus Therapeutics from $17.00 to $16.00 and set an "underweight" rating for the company in a research report on Wednesday. Wells Fargo & Company dropped their target price on shares of Arcturus Therapeutics from $105.00 to $98.00 and set an "overweight" rating on the stock in a research report on Wednesday. Finally, Cantor Fitzgerald reiterated an "overweight" rating on shares of Arcturus Therapeutics in a report on Monday, May 9th. Four research analysts have rated the stock with a sell rating, two have given a hold rating and two have assigned a buy rating to the company. According to MarketBeat.com, the company has an average rating of "Hold" and an average target price of $38.75.
Hedge Funds Weigh In On Arcturus Therapeutics
A number of hedge funds have recently added to or reduced their stakes in ARCT. Federated Hermes Inc. increased its position in shares of Arcturus Therapeutics by 1.8% during the 1st quarter. Federated Hermes Inc. now owns 3,761,900 shares of the biotechnology company's stock valued at $101,421,000 after purchasing an additional 66,971 shares during the last quarter. State Street Corp boosted its holdings in shares of Arcturus Therapeutics by 56.5% in the first quarter. State Street Corp now owns 3,217,957 shares of the biotechnology company's stock worth $86,756,000 after acquiring an additional 1,161,883 shares during the period. Vanguard Group Inc. grew its position in shares of Arcturus Therapeutics by 0.5% in the first quarter. Vanguard Group Inc. now owns 1,153,513 shares of the biotechnology company's stock valued at $31,099,000 after purchasing an additional 6,291 shares in the last quarter. Goldman Sachs Group Inc. raised its stake in shares of Arcturus Therapeutics by 3.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 281,990 shares of the biotechnology company's stock valued at $7,602,000 after purchasing an additional 8,666 shares during the period. Finally, Dimensional Fund Advisors LP lifted its holdings in Arcturus Therapeutics by 190.3% during the 1st quarter. Dimensional Fund Advisors LP now owns 217,572 shares of the biotechnology company's stock worth $5,866,000 after purchasing an additional 142,633 shares in the last quarter. Institutional investors and hedge funds own 80.10% of the company's stock.
Arcturus Therapeutics Company Profile
(Get Rating)
Arcturus Therapeutics Holdings Inc, an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company's development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lung disease caused by mutations in cystic fibrosis transmembrane conductance regulator (CFTR) gene, as well as vaccine programs include LUNAR-COV19 and LUNAR-FLU.
Featured Articles
- Get a free copy of the StockNews.com research report on Arcturus Therapeutics (ARCT)
- The How And Why of Investing in Oil Stocks
- The How and Why of Investing in Gold Stocks
- Workhorse Group Is Ready To Get Back On The Horse
- A Rounded Bottom In Draftkings, Inc Begins To Reverse Course
- Are 3M, Honeywell, GE Buys After Quarterly Reports?
Receive News & Ratings for Arcturus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcturus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
